Dissecting DELIVER: Dosing, Non-Polymer Binding Implicated In Guidant Trial
This article was originally published in The Gray Sheet
Executive Summary
The role of insufficient dosing in the DELIVER trial evaluating Guidant's Achieve drug-eluting stent will likely emerge in presentations at the American College of Cardiology's annual meeting in Chicago March 30-April 2
You may also be interested in...
Boston Scientific Taxus
First PMA module for paclitaxel-eluting coronary stent is submitted to FDA. The fifth and final module will be submitted in June and include TAXUS IV clinical trial data. The results will be presented at the Transcatheter Cardiovascular Therapeutics meeting in Washington, D.C. in September (1"The Gray Sheet" Feb. 3, 2003, p. 4)...
Boston Scientific Taxus
First PMA module for paclitaxel-eluting coronary stent is submitted to FDA. The fifth and final module will be submitted in June and include TAXUS IV clinical trial data. The results will be presented at the Transcatheter Cardiovascular Therapeutics meeting in Washington, D.C. in September (1"The Gray Sheet" Feb. 3, 2003, p. 4)...
EU Taxus Approval, Passive Coating Option Expand Boston Scientific’s Reach
Boston Scientific projects that European conversion rates from bare-metal to drug-eluting stents will range 20-50% in 2003, as reimbursement trends improve